mention in biotech report

http://rogermontgomery.com/a-new-drug/

One of our brokers and a producer of some excellent insights into smaller capitalized companies in Australia, Baillieu Holst, recently attracted the skills of analyst Stuart Roberts who has wasted no time releasing a new 37 page report covering the Life Sciences sector. As many private investors rarely have a comprehensive understanding even of the players in this sector, I thought it would very useful to provide you with Baillieu’s summary (with permission) of each of the companies covered.

For those interested in opening an account with Baillieu and gaining access to their research, send an email to Andrew [email protected].

According to the report (see warning) Baillieu’s three top picks are: Alchemia (ACL) expecting Phase III data next year on a new cancer drug formation; Neuren (NEU) with its potential blockbuster CNS drug NNZ-2566; and Bionomics (BNO) also expecting data early next year on its BNC105 cancer drug.

Also note, Montgomery Funds own shares in Sirtex.

PLEASE READ THE IMPORTANT WARNING AND DISCLAIMERS BELOW

Alchemia (ACL) is in Phase III with HA-Irinotecan, a new formulation of an old cancer drug. Data from this metastatic colorectal cancer trial is due in the first half of calendar 2014. Phase II suggested a strong improvement in Progression-Free Survival for these patients.

Admedus (AHZ) has gained CE Mark approval for its first product, a cardiovascular tissue patch called CardioCel. Admedus is also seeking to be a player in the emerging field of DNA vaccines, backing the Gardasil inventor, UQ Professor Ian Frazer.

Bionomics (BNO) licensed the anxiety drug BNC210 to America’s Ironwood in 2012 for a massive US$345m in upfront and milestone payments. Bionomics’ BNC105 cancer drug reads out important Phase II data early next year.

Mesoblast (MSB) is pioneering the exciting field of regenerative medicine. The company has numerous stem cell trials ongoing including several Phase IIIs. An important partnership with Teva, one of the world’s largest pharma companies, is moving forward.

Nanosonics (NAN) is now earning revenue from trophon EPR, which disinfects ultrasound probes. This product has potential to become a healthcare industry standard, helped by GE, which is trophon EPR’s North American distributor.

Neuren (NEU) is developing NNZ-2566, now in Phase II in Traumatic Brain Injury (TBI) and in a rare condition called Rett Syndrome. Clinical success in either indication makes a potential blockbuster. The US government is funding the TBI trial.

Phosphagenics (POH) has developed the world’s first patches delivering the painkilling drugs oxycodone and oxymorphone. These products go to Phase II next year. Various potentially valuable collaborations related to transdermal drug delivery are ongoing.

REVA Medical (RVA) has developed one of the world’s first bioresorbable stents. This polymer-based product, called ReZolve, is now in a pivotal trial for potential CE Mark approval in 2015. We expect the product can help double a US$4-5bn global market for stents.

Sirtex Medical (SRX) now has a $100m-a-year business in its SIR-Spheres -radioactive beads for the treatment of liver cancer. We foresee a big jump in sales from 2015 once data from the first of a number of large clinical trials of SIR-Spheres is released.

Tissue Therapies (TIS) has, in VitroGro ECM, a compelling wound healing product for the treatment of venous and diabetic foot ulcers, but its European launch has been delayed by regulatory issues. Resolution of these issues could substantially re-rate the stock.